Most Read Articles
Stephen Padilla, 31 Jan 2020
The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.
02 Jun 2020
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.

Product Highlight - OZEMPIC

16 Sep 2020

The only once-weekly type 2 diabetes treatment unifying superior efficacy and CV benefits1

  • Up to 1.8% HbA1c reduction*1,2
  •  Up to 6.5kg weight reduction*1,2
  •  26% CV risk reduction vs placebo†1,3

  *Results apply to Ozempic 1 mg vs Dulaglutide 1.5 mg

 †When added to standard of care, which included oral anti-diabetic treatments, insulin, anti-hypertensives, diuretics and lipid-lowering therapies1,4



References:
1. Ozempic Malaysia Prescribing Information.
2. Pratley RE, et al; Lancet Diabetes Endocrinol. 2018;6(4):275-286.
3. Marso SP, et al; N Engl J Med. 2016;375(19):1834-1844.
4. Marso SP, et al; N Engl J Med. 2016;375(suppl 1):S1-S108.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 31 Jan 2020
The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.
02 Jun 2020
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.